Annual blood samples from 47 women who later developed acute myeloid leukemia led researchers to estimate that two thirds acquired their first mutation before age 20, with each subsequent mutation increasing mutant cell growth rates by a factor of 2–3
Annual blood samples from 47 women who later developed acute myeloid leukemia led researchers to estimate that two thirds acquired their first mutation before age 20, with each subsequent mutation increasing mutant cell growth rates by a factor of 2–3
On 11 November, Nature published a study from the University of Cambridge and University College London on blood cell clones. These are the descendants of a single stem cell whose mutation allows it to multiply faster than neighboring cells. Within a clone, mutations of the same kinds found in leukemia accumulate one after another.
Many older people have these clones, but few develop leukemia. Identifying what distinguishes those who will develop the disease requires blood samples collected years before diagnosis. The UKCTOCS trial provided such samples: 50 640 women aged 50–74 gave blood annually for ovarian cancer screening for up to 11 years. The blood typically stood for about 22 hours before centrifugation, allowing white blood cells to rupture and release their DNA into the serum.
Clones were found in 72% of 46 healthy women of similar ages and 89% of 47 women who later developed leukemia. In the healthy women, clones usually remained small and stable. In those who later developed leukemia, clones were larger, changed markedly in size, and competed with one another. In at least a third of the women who developed leukemia, a single clone had taken over the entire blood cell population long before diagnosis. This never occurred in the healthy women.
A clone with one mutation grew by 10–30% per year and doubled in size within 2–7 years. A clone with four mutations grew by 100–1000% per year, doubling within weeks or months. Each new mutation increased the growth rate by a factor of 2–3. By extrapolating the clones' growth curves backward, the authors estimated that two thirds of the women had acquired their first mutation before age 20. On average, the first mutations appeared more than 50 years before diagnosis, and the second mutations appeared 30 years before diagnosis. Over decades, a clone slowly accumulated cells, and the more cells it contained, the greater the chance of another mutation.
“Once a clone is established, its current growth rate shows where it will be years or even decades later,” says study lead Jamie Blundell. A simple model closely reproduced the clones' trajectories. Each clone had two parameters, its time of emergence and its growth rate, and clones competed only for the available space in the blood cell population.
To test whether these rules could explain how often the disease occurs, the researchers simulated 200 200 virtual people. Mutations arose at random, each typically multiplying a clone's growth rate by 2,5, while the remaining inputs came from previous studies. Leukemia was defined as a clone with four mutations that accounted for more than half of the blood cell population. Such a clone arose before age 85 in 0,47% of the virtual people, compared with 0,48% in the real population, according to Cancer Research UK.
When a clone takes over the entire blood cell population, its mutation appears in DNA sequencing data as though it had been present from birth, because every cell carries it. Standard analyses therefore often classify it as an inherited variant and discard it. Among 420 054 UK Biobank participants, 388 had a known blood cell clone mutation present in more than 30% of their DNA sequencing reads. Myeloid leukemia subsequently developed in 42 of them (11%) and in 474 of the remaining 419 666 participants (0,11%).
Because clones grow exponentially, the authors suggest that even a small reduction in growth more than ten years before diagnosis could substantially reduce the number of cells and the chance of another mutation. For a clone carrying a mutant IDH2 enzyme, they propose an inhibitor of that enzyme and a vaccine against mutant proteins as possible interventions.
Reviewer No. 3 challenged the conclusion that factors outside the clone play a secondary role in the article's peer review file. The authors agreed that the data allow for external influences, while maintaining that the clones' intrinsic growth rates suffice to explain their trajectories. Such an external influence has been found in mice: aging support cells in the bone marrow helped a mutant clone grow.
- https://www.nature.com/articles/s41586-026-11269-x
- https://www.cam.ac.uk/research/news/fossil-record-in-stored-blood-samples-lets-scientists-trace-leukaemia-back-decades-before-diagnosis
- https://static-content.springer.com/esm/art%3A10.1038%2Fs41586-026-11269-x/MediaObjects/41586_2026_11269_MOESM4_ESM.pdf
- https://t.me/UkhvatNews/2997